International Conference and Expo on Biopharmaceutics September 21-22, 2015 Baltimore, MD, USA

He is a member of the American Chemical Society, Controlled Release Society, American Association of the Pharmaceutical Sciences and other professional organizations, active on the conference circle and serves as a co-chair of the Formulation and Drug Delivery Committee of the Massachusetts Biotechnology Council.

Sinerik Ayrapetyan has completed his Ph.D and postdoctoral studies from Ukraine Academy of Sciences. He is the president of Life Sciences International Postgraduate Educational Center and head of UNESCO Chair in Life Sciences. He is the author of 7 books and 185 papers in refereed journals, and is serving as a member of Editorial Board of ISRN Biophysics, the Board of Associate Editors for the "Electromagnetic Biology and Medicine" Journal, Associate Editor for Biomedical Research of "Journal of International Dental and Medical Research".

Metabolic regulation of excitable cell membrane function

Rosemarie Truman: Rosemarie Truman is the Founder and CEO of The Center for Advancing Innovation. She is also one the Board of Directors of Medical Center of the Americas Foundation and strategy graduate school professor. She has over 22 years of experience in strategy, having led over 120 innovation and strategy engagements for the top 20% of the Fortune 50 as well as start-ups and government organizations. She conceived, launched and spearheaded IBM’s global innovations and R&D strategy, organization and trade secrets growth strategies for identifying breakthroughs in Life Sciences and other industries. Having been featured in Nature, Wired, the Chicago Tribune, Licensing Executive Society, and more, she has received several noteworthy awards such as the Health and Human Services Secretary’s Pick Innovation award, the Federal Laboratory Consortium Technology Transfer Excellence award as well as the Golden Circle award given to 200 of 450,000 of IBM’s employees.

Dr. Dai currently serves as Vice Chair of Physical Pharmacy and Biopharmaceutics (PPB) section in AAPS. Additionally, he is the current President of Sino-American Pharmaceutical Professionals Association (SAPA)-Greater Philadelphia. SAPA is a nonprofit and pharmaceutical professional organization with over 4,000 members.

Dr. Dai’s research and innovation have focused on improving both biological and small molecule drug products through design and development of novel formulations, proprietary delivery technologies and processes. His technology innovations have directly led to the launch of a current commercial delivery-enhanced product by Johnson and Johnson, and established the development projects for clinical trials.

Gjumrakch Aliev, M.D, Ph.D., the internationally recognized founder of Gally International, has more than a decade of research in the area of gerontology. Dr. Aliev's extensive research is respected throughout the world and held in the highest regard. Dr. Aliev is one of the few scientists internationally recognized for his expertise in vascular and mitochondria factors in the pathogenesis of gerontology research fields especially in the atherosclerosis, ischemia/reperfusion, stroke, AD and on the models representing these conditions. He received postdoctoral training under the prestigious British Hearth Foundation Grant Program in the University College London (advisor Professor Geoffrey Burnstock, FRS) in the specialty neurosciences cardiology and medicine. Professor Aliev have developed research and educational programs in neuroscience, neurodegeneration, mitochondrial, cardiovascular, cerebrovascular, pathology, anatomy, histology, cancer, electron microscopy and other areas. Additionally, he has extensive experience managing dynamic academic research and teaching environments.

Hartmut Derendorf, PhD is Distinguished Professor and Chairman of the Department of Pharmaceutics at the University of Florida. He has published over 380 scientific publications and is Associate Editor or Editor of several journals. He has served as President of the American College of Clinical Pharmacology (ACCP) and President of the International Society of Anti-infective Pharmacology (ISAP). He was awarded the Distinguished Research Award and the Nathaniel T. Kwit Distinguished Service Award of ACCP, the Research Achievement Award in Clinical Science of the American Association of Pharmaceutical Sciences (AAPS) and the Volwiler Award of the American Association of Colleges of Pharmacy (AACP).

Mircea Alexandru Mateescu has a PhD from Bucharest Polytechnic University and is a receiver of a “Honorary Laurea” from Rome University “La Sapienza”. He has been a full-time Professor at UQAM since 1994. His research relates to Multifunctional Proteins and to Drug Targeting. He is the Co-inventor of more than 30 patents covering therapeutic enzymes and new excipients for drug delivery. He has developed fruitful collaborations with pharmaceutical companies and was involved in several technological transfers. He published more than 130 papers in reputed journals, one book and 8 book-chapters. He is the holder of Bombardier Prize (1999) for Technological Innovation, of Venezia Prize (Italian Chamber of Commerce, 2012), and Research-Career Prize (UQAM, 2014).

Jorg Kreuter studied Pharmacy at the Philipps-University Marburg, Germany and got his PhD in 1974 as well as his Habilitation (Science Doctor) in 1982 at the Eidegenössische Technische Hochschule (ETH) in Zürich, Switzerland. In 1977, he was working as a Postdoc at the University of Kansas in Lawrence and in 1979, at the University of Michigan in Ann Arbor. In 1983, he was a Visiting Professor at the University of Wisconsin in Madison and in 1984 he became a Professor at the Goethe-University of Frankfurt, Germany. He was Dean twice, between 1988-1989 and 1997-1998. He is one of the pioneers in nanoparticles and has over 300 publications.

Dr. Zhang obtained his MD with highest honor in 1983 and PhD in Toxicology and Occupational Epidemiology in 1988, from Shanghai Medical University (now Fudan University Shanghai Medical College), China. He completed his post-doctoral clinical pharmacology fellowship at University of Alabama School of Medicine (UAB) between 1989 and 1992. He joined UAB faculty in 1992 and moved through the ranks to Tenured Professor and Cancer Pharmacology Laboratory Director. In July 2010, he joined TTUHSC School of Pharmacy as Tenured Professor and Chair. With over 20 years of experience in the field of translational biomedical research, particularly in the area of translational medicine, cancer therapy and prevention, clinical pharmacology and therapeutics, pharmaceutical and toxicological research, Dr. Zhang’s research has been continuously funded by NIH, DoD, and other agencies. He has been invited to give more than 110 presentations for prestigious universities, institutions, and organizations. He has published more than 170 papers, 2 books, more than 45 invited reviews/book chapters, and more than 150 meeting abstracts. Dr. Zhang’s publications have been cited more than 6300 times. Dr. Zhang is a certified toxicologist by the American Board of Toxicology (D.A.B.T.) and has served on Board of Directors of ABT since 2009. He has been an FDA advisory committee member since 2003 and served as a panel member for NIH, DoD, CDC, FDA, and NIOSH and other international panels, including China’s National Nature Science Foundation (NSFC). For his outstanding contributions in sciences, Dr. Zhang was elected as a Fellow of American Association for the Advancement of Science (AAAS) in 2009, a high national honor.

Translational medicine, cancer therapy and prevention, clinical pharmacology and therapeutics, pharmaceutical and toxicological research.

In this laboratory we study the relationship between the cardiovascular gene family and the various phenotypic changes (cell proliferation,adhesion and apoptosis) that lead to the inititation and progression of atherogenesis. We are also interested in alternative medicine drug discovery to prevent atherosclerosis.Our model systems are cultured human cells of the vascualr wall and animal models of athersclerosis.We also employ transeosophageal MRI technology to image atherosclerotic plaques and their rupture and regression in collaboration with the JHU-SOM faculty. Our laboratory has discovered that multiple risk factors in atherosclerosis such as oxidized LDL, shear stress,nicotine,all converge upon a lactosylceramide synthase gene to produce lactosylceramide. In turn, lactosylceramide serves as a lipid second messenger that activates an "oxygen sensitive signal transduction pathway" leading to cell proliferation and cell adhesion. We are also focusing on the neutral sphingomyelinase gene that is upregulated by inflammatory molecules such as Fas Apo1(CD95) , tumor necrosis factor and stress that leads to apoptosis. Since apoptosis of the aortic smooth muscle cells is a hallmark in the pathophysiology of plaque rupture we want to understand its biochemical/molecular basis involving this gene/function. Our herbal drug discovery strategy involve purification and characterization of small molecules employing high-performance liquid chromatography,GC-MS technology. Such well characterized molecules are then employed to determine their efficacy in abrogating atherogenesis and plaque rupture employing animal models.

Robert Makuch is a professor in the Department of Biostatistics at the Yale School of Public Health and Director of the Regulatory Affairs Track. A graduate of the University of Connecticut (BA), University of Washington (MA – mathematics), and Yale University (MPhil, PhD), Professor Makuch worked at the National Cancer Institute (NCI) and the World Health Organization’s International Agency for Research on Cancer early in his career. He also was heavily involved in HIV research from the mid 80's through the early-mid 90's. He participated on the data monitoring committee for the original AZT vs. placebo randomized clinical trial in AIDS patients, and served on numerous committees for the NCI and the National Institute of Allergy and Infectious Diseases. He returned to Yale in 1986, and has worked extensively on methodologic issues in clinical trials and large population-based studies since. Another area of interest involves detection of rare adverse drug events, especially in the post-marketing environment. These area of methodologic research evolved as a result of his continued interest (since the mid 80s) in regulatory affairs science. In addition, Makuch developed a regulatory affairs track at YSPH for its students, and over the past 4 years has been the leader of numerous training programs for senior delegations of the Chinese Food and Drug Agency. His areas of medical application include cancer, HIV, arthritis, and cardiovascular disease.

Adeboye Adejare received BS (1978) and MS (1980) in Chemistry from University of Iowa followed by Ph.D. in Medicinal Chemistry from The Ohio State University (1985). He did postdoctoral studies at the NIH prior to beginning career in academia and rising to the current position of Professor. His research is geared towards discovery of novel compounds that can be used to probe CNS disorders, pharmaceutical profiling, and drug targeting. He has over 40 publications, several issued patents, and over 100 meeting presentations. Many of his former students and postdoctoral associates are employed in academia and the pharmaceutical industry.

Drug targeting Mechanisms of neurodegeneration Chemistry of fluoroaromatic compounds Pharmaceutical profiling

Amr Amin is a Professor of Cell & Molecular Biology and a graduate faculty at UAE University. He earned his PhD in Cell & Developmental Biology from University of Illinois at Chicago and received a postdoctoral training in Molecular Genetics at University of Pennsylvania School of Medicine. After joining UAEU, Dr. Amin’s focus was redirected to the field of preventive medicine. His lab is interested in natural product-based protection against cancer. Most recently, his lab has been employing non-invasive approaches and nanoparticles to learn more about the molecular aspects of chemoprevention particularly against liver cancer. He published many research articles, reviews and book chapters in reputable journals. He also serves on the editorial boards and as a reviewer of many international journals. Dr. Amin is also the recipient of many national and international awards.

Amr Amin research interests focus biology and chemoprevention of cancer, preclinical studies, and novel plant-based anticancer drugs.

Dr. Do received his B.S. from the University of Georgia and Ph.D. in pharmaceutical sciences (pharmaceutics) from Mercer University, College of Pharmacy & Health Sciences. His research interests are in the areas of cancer epigenetics, drug delivery systems, dosage form formulation, microencapsulation technology, and pharmaceutical compounding. Dr. Do has over 60 publications and presentations. Currently, he serves as a copyeditor for European Journal of Chemistry, as a member of the Editorial Board for nine journals and as a reviewer for over fourteen scientific journals. Additionally, Dr. Do has served as an abstract and grant reviewer for several organizations. In regards to teaching, he has taught pharmaceutics courses, including advanced drug delivery systems, pharmaceutical dosage forms, pharmaceutical compounding and pharmacokinetics. Dr. Do is a member of several scientific and professional organizations, including the American Association of Colleges of Pharmacy (AACP), the American Association of Pharmaceutical Scientists (AAPS) and the Regulatory Affairs Professional Society (RAPS).

Gulay Buyukkoroglu has completed her Ph.D at the age of 33 years from Anadolu University and postdoctoral studies from University of London The School of Pharmacy on transcutaneous DNA vaccination. She is head of Pharmaceutical Biotechnology at Anadolu University Faculty of Pharmacy. She is working on gene delivery systems, new cancer drug delivery systems with siRNA and specific antibodies attached drug delivery systems and DNA vaccination.